Ethics & Informed Consent: Retrospective Case-Control Study (China)

1. Ethical Principles & Legislative Framework

In research involving human participants, securing ethical clearance is a critical first step. For a Retrospective Case-Control Study being conducted in China, study designs must align with the primary regulatory legislation: Measures for Ethical Review of Life Science and Medical Research Involving Humans. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.

Administrative review and formal approval are managed by a local or regional Institutional Ethics Committee. Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.

2. Study Design Elements & Reporting Integrity

For a Retrospective Case-Control Study, the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.

Study Classification: Minimal Risk (Exempt or Expedited)

Case-control studies rely on historical data extraction. When active consent is unfeasible, a waiver can be requested by proving secure de-identification and minimal participant risk.

To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: STROBE guidelines.

3. Informed Consent & Information Sheet Guidelines

A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:

• Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
• Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
• Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under Personal Information Protection Law (PIPL).
• Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
• Ethics Board Contact Information: Provide the contact details of the reviewing Institutional Ethics Committee so participants can reach out if they have questions or concerns.

Research Ethics, Clinical Trials & Institutional Governance

Conducting data collection for this observational Retrospective Case-Control Study in China requires addressing passive ethical considerations in research. Observational registries in China must pay special attention to vulnerable populations research ethics when storing health metrics. Every registered subject must review a comprehensive research consent form that explains how records are linked and stored. Depending on the de-identification pipeline, some database studies may qualify under irb exempt research criteria. Observational cohorts retrieving biospecimens must declare their laboratory safety ratings from biosafety level 1 2 3 4. Ethical oversight committees in China audit the study's consent registry periodically to verify compliance with national legal statutes.

4. Regulatory Checklist Table

To streamline your ethical review submission, use the structured alignment checklist below:

6. Frequently Asked Questions